Elanco Animal Health Inc has decided against acquiring Bayer AG's Canadian distribution rights to several poultry insecticides, Canada's Competition Bureau said on Tuesday, as it looks to complete a $7.6-billion deal. The U.S.-based company will also divest its canine ear infection treatment product Osurnia and Bayer's feline dewormer Profender to address competition concerns about its acquisition of the German firm's veterinary drugs unit. The Competition Bureau said Elanco and Bayer's animal health unit were each other's closest rivals in several Canadian markets and a potential combination would result in a substantial decrease in competition.
Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.
Bayer <BAYGn.DE> was forced on Wednesday to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims. The German company said that lawyers representing those preparing a class action had withdrawn a request for court approval of the $1.25 billion future claims scheme, part of a broader $10.9 billion agreement to settle close to 100,000 U.S. lawsuits related to Roundup. The move would give both sides more time to address questions raised by Federal District Court Judge Vince Chhabria of the Northern District of California who presides over the federal Roundup litigation, Bayer said.